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Summary 
Chronic lymphocytic  leukemia (CLL) is characterized by the clonal expansion of CD5-expressing 
B lymphocytes. Most studies have found that these leukemic CD5 + B cells, like their normal 
counterparts,  use immunoglobulin (Ig) variable (V) region genes that exhibit minimal, if any, 
somatic diversity. These and other observations  have suggested  that  CD5 §  B cells may be 
incapable of generating Ig V gene diversity, and therefore may not be able to develop higher 
affinity binding sites that could be selected by antigen.  However, most of the studies of CLL 
and normal CD5 + B cells have focused on IgM-producing cells. Since somatic mutations are 
most often seen  in B cells that have undergone an isotype class switch, we analyzed the Ig heavy 
(H) and light (L) chain variable region genes of seven IgG +  CD5 + CLL B cells to determine 
if somatic diversification and antigen selection had occurred. The data derived provide evidence 
for skewed use, somatic diversification,  and antigenic selection  of  the Ig V region genes. Nonrandom 
use of both H and L chain V region genes was manifested by an overrepresentation of VH4 and 
V~I family genes and the underrepresentation  of the JH4 gene segment.  Furthermore, VH4 gene 
use was restricted to only two family members (4.21 and 4.18). In four of the seven cases, the 
V.  and  VL  genes  displayed />5% difference from  the most  homologous known germline 
counterparts.  Polymerase chain reaction and Southern blot analyses performed in two of these 
patients demonstrated that their unique V. CDR2 and adjacent sequences were not present in 
their germline DNA. In addition,  a significant level of diversity was seen in the rearranged DJ8 
segments  and  at  the  VL-JL junctions  of every patient  that  occurred  both  at  the  time  of 
recombination and subsequently. The localization of replacement changes to complementarity 
determining regions of some patients suggested that antigen selection had occurred. Furthermore, 
the mutations identified in the V~ and VL genes of each individual patient were strikingly similar, 
both in number and location. Collectively, the data indicate that a subset of CD5 § CLL B cells 
can display Ig V region gene mutations.  In addition,  they are consistent with the notions that 
in some cases antigen selection of these mutations may have occurred, and that antigen stimulation 
may be a promoting factor in the evolution  of certain CLL  clones. 
C 
hronic lymphocytic  leukemia (CLL)  1 is characterized by 
an overexpansion of a clone of human B cells that al- 
1Abbreviations used in this paper: CDR,  complementarity  determining 
region; CLL, chronic lymphocytic leukemia; FR, framework region; RT, 
reverse transcriptase. 
This work was  presented  in part  at  the International Conference  on 
Polyreactive and Monoreactive  Antibodies  in Natural  Immunity and 
Autoimmune  Diseases held at the National Institutes of Health, Bethesda, 
MD,  23-25  September 1992. 
most invariably expresses surface membrane CD5 (for a re- 
view see reference 1). Over the years, investigators  have studied 
these cells to understand both the normal physiology of this 
subset of human B cells as well as the abnormal features of 
the B lymphocytes expanded in this disease. Studies to date 
suggest that the B cells that are clonally expanded in CLL 
use a biased set of Ig V genes (for a review see reference 2) 
to code for low affinity, polyreactive autoantibodies  (3-5), 
predominantly  of the IgM class. Although numerous studies 
have noted that these Ig V genes rarely undergo somatic mu- 
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et al.  (6),  which documented V, gene mutations  among a 
cohort  of CLL patients  whose malignant  clone  used the 
V~251 gene. Surprisingly, however, a follow-up study (7) of 
a larger, well-characterized group of patients whose leukemic 
cells used the same gene failed to confirm these findings, thus 
leaving this dilemma unresolved. 
It is important to note, however, that most of these studies 
of CD5 § CLL B cells have dealt with IgM-producing cells. 
Since antigen stimulation resulting in somatic diversification 
may occur more  often  at  the  time  of or  among  isotype- 
switched B cells (8), CD5 + B cells producing non-IgM an- 
tibodies may exhibit different features, both at the protein 
and nucleic acid levels. To test this hypothesis and to help 
resolve the issue of the capacity of these cells to somatically 
diversify their Ig V genes, we have analyzed the Ig V genes 
used by CD5 + CLL cells that produce IgG antibodies. The 
data  demonstrate  an  overrepresentation  of Ig  V.  and  V~ 
family genes and an underrepresentation of a frequently em- 
ployed J. segment. In addition, there is strong evidence that 
the Ig V  gene segments of both the H  and L chains from 
several of these CD5 + CLL clones have undergone somatic 
mutation. Finally,  the location of replacement substitutions 
suggests that  some of these mutations  may have been an- 
tigen driven  and selected. 
Materials and Methods 
CLL  Cells and Heterohybridomas.  Seven patients  with  CLL 
whose CD5 § leukemic B cell clones produced IgG were studied. 
As recently reported (9), each patient exhibited clinical features typ- 
ical for CLL, with stages ranging from 0 to IV (Rai classification; 
10). In addition, all exhibited an expanded population of circulating 
IgG+CD5 + B  cells as determined  by immunofluorescence,  al- 
though the percentages of IgG+CD5 + coexpressing cells varied 
among the various patients  (range: 64-92%). Serologic and im- 
munofluorescence studies demonstrated that five  of these CLL clones 
produced IgG1 and two IgG3  (11). 
Heterohybridomas made with these cells were screened for the 
secretion of Ig H and L chains that corresponded to the original 
CD5 + CLL B cell, and appropriate lines were cloned by limiting 
dilution to ensure monoclonality (9). V gene fingerprinting  anal- 
yses (11, 12) were performed to confirm that the V. and VL genes 
used by the heterohybridomas were derived from the CLL clones 
overexpanded in vivo. All seven hybridomas expressed V, CDR3 
lengths identical with those of the CLL cells (9). More recent studies 
indicated  that  six  of the  hybridomas  had  identical  VL CDR3 
lengths. Since the fingerprinting results for hybridoma no. 039 were 
equivocal, the DNA sequence of this gene was determined from 
the circulating  CLL cells. 
Reverse Transc@tase  (RT) PCR.  The primers for the V, and VL 
families and C. and ~  amplification were as reported in references 
13 and 14, respectively.  Total RNA (500 rig) was reverse transcribed 
by use of avian myeloblastosis virus KT (GIBCO BRL, Gaithers- 
burg, MD) and the appropriate C. or C~ primer, and then specific 
amplification of the cDNA was accomplished as described (15). 
Cloning and Sequencing of PCR Products.  PCR products were 
force cloned into  the pUC19 vector after digestion with EcoRI 
and HindlII. Clones were isolated and sequenced in both direc- 
tions by the Sanger dideoxy chain termination method (16), either 
manually or by an automated  sequenator (model 373A; Applied 
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Biosystems, Inc., Foster City, CA) using the DyeDeoxy  TM termi- 
nator  kit (Applied Biosystems Inc.). 
Southern Blot Analyses.  Genomic DNA was amplified by PCK 
with selected primers, electrophoresed through  1% agarose gel, 
transferred onto nylon membranes (Separation, Inc,. Westboro, 
MA), and UV cross-linked as described previously (15). Blots then 
were hybridized with 32P-labeled probes in hybridization solution 
(QuikHyb; Stratagene Inc., LaJolla, CA) according to the manufac- 
turer's instructions. When appropriate, stripping was accomplished 
by incubation at 72~  for 1 h in 2.5 mM Tris-HCl (pH 8.0), 0.1 
mM EDTA, and 0.5 mM sodium pyrophosphate. After washing, 
blots  were  exposed  overnight  on  photographic  film (XAKS; 
Eastman Kodak Co.,  Rochester, NY). 
Results 
VH Gene Segment  Analyses 
Fig.  1 lists the Ig V. gene sequences determined.  Com- 
puter comparisons (17) of these with their presumed germ- 
line counterparts  indicated  the following features. 
Biased  VH Gene  Usage,  Only  two  gene  families  were 
used,  with  five patients'  cells using V.4 family genes and 
two V.3 family genes. Of the 12 or more members of this 
moderately sized family (18), only 2 were represented in this 
group:  V.4.21  (n  =  3;  patients  001,  033,  and  055)  and 
V~4.18 (n  --  2; 039 and 057). Because of the small number 
of V~3 genes found,  no conclusions about gene frequency 
use can be drawn. 
Different Degrees of Similarity  with Germline Genes.  Two 
of the VH4 CLL samples (patients  039 and 057) exhibit  a 
high degree of homology (>98.5%) with the presumed germ- 
line ancestor (Fig.  1), whereas the other three (001, 033 and 
055) display considerably less identity (95, 92, and 91%, respec- 
tively). Similarly,  one of the V.3 cases (040) is highly  ho- 
mologous with a germline gene (>98.5%),  whereas much 
less similarity (94%) is observed in the other (030). The three 
V,4 CLL B cdls that show significant differences from their 
ancestral gene (<95% homology; 001, 033, and 055) all use 
the V, 4.21 gene.  Those patients using the V. 4.18 gene ex- 
hibit >98.5%  homology to the germline. 
Differences in Distribution of Nucleotide Changes.  For certain 
patients (001 and 033), the differences from the ancestral genes 
are located throughout the V, segment (Fig.  1), whereas for 
others (030 and 055), differences are nonrandomly distributed. 
In these latter two patients, the differences cluster predomi- 
nantly within complementarity determining region (CDR)2 
for patient 030 and within CDK2 and FR3 for patient 055. 
Differences in Deduced Amino Acid Sequences.  When the 
nucleotide differences  of the patients are analyzed for their 
effects on the amino acid sequence of the deduced Ig H chain 
proteins (Fig. 2 A), there are striking differences in replace- 
ment/silent (R/S) substitution ratios for certain patients. For 
example, for patient 030,  the K/S of CDK 1,2 is 7.0 and 
that of framework regions (FR) 1,2,3 is 0.6. In contrast, for 
patient  033,  the K/S in  CDK  1,2  is 0.8 and in  FR  1,2,3 
is  1.3.  Patient  055 illustrates  an overall  R/S for CDK  1,2 
of 1.7 and for FK 1,2,3 of 1.3, although most of these latter 
substitutions  occur in a defined region  of FK3. 
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Figure  1.  Nucleotide sequences  of V. genes. The V. germline genes most homologous  to the individual CLL V. genes are listed on top.  These 
sequence  data are available from EMBL/GenBank/DDBJ  under  accession numbers  X84333-X84339. 
Absence of the Patient-specific Sequences in Germline DNA 
Next we investigated whether the differences in the V. 
gene segments observed in patients 030 and 055 were somat- 
ically generated. These patients were chosen since their V. 
sequences were significantly different from the presumed germ- 
line counterparts, and these differences clustered within areas 
of the gene that would likely directly influence the shape of 
the antigen-binding  groove. 
PCR Analyses.  The first approach involved the construc- 
tion of two sets of PCR. primer pairs, one that would allow 
amplification of a region encompassing the entire CDP.2 and 
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portions of FR2 and FR3 of all genes of the two families 
involved (V.3 and V.4),  and another set for amplification 
of only the unique  sequences from the two individual pa- 
tients (CDR2 for patient 030 and CDR2 plus part of FR3 
for patient 055).  The former are designated G for general 
primers, and the latter S for specific primers. These primer 
pairs were used to amplify either unrearranged neutrophil 
DNA or rearranged lymphocyte DNA. Fig, 3 indicates the 
results obtained for patient 055. 
Fig. 3, Lanes 1 and 2 indicate the positions  in the gel of A  H  CLqZ  R' 
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Figure  2.  Deduced amino acid sequences of the H and L chains, The amino acid sequence of the germline gene is given through FR 3, with the 
CLL  sequences listed below.  Sequences of each CLL CDR3 and FR4 are presented. (A) H  chain.  (B) L chain. 
the  V~  4.21  segment  amplified  from  RNA  by  RT/PCR 
with the G and S primer pairs, respectively.  Amplification 
of both germline (lane 3) and rearranged (lane 5) DNA with 
the G  primer  set  resulted  in appropriately  sized  products. 
Amplification of the same DNA with the S primer pair (lanes 
4 and 6) failed to reveal readily detectable  bands.  Since the 
inability to consistently amplify a product may be due to gene 
copy number, aliquots (1/xl) of the products of the G primer 
Figure  3.  Absence of CLL 055-specific sequences in germline DNA 
as assessed  by PCR. Gel indicating  PCR fragments amplified from various 
nucleic acids by use of the general primer pairs (G: 55.G.Fwd.: 5'AGG- 
GTCTGGAGTGGATTGGG and 55.G.Rev. 5'ACTTCAGGGAGAACT- 
GGTTC) and specific (S: 55.S.Fwd. 5'GAGGTCAGTCATACTGGAAC 
and 55.S.Kev. 5'GAACTGGTTCATTGGAATGC).  Note the absence of 
a CLL 055-specific  fragment  in lane 7 containing the products of the 
reamplified neutrophil DNA from lane 3.  In contrast, an appropriately 
sized product is detected in lane 8 after reamplification of the CLL DNA 
from lane 5. 
amplifications from both unrearranged and rearranged DNA, 
which should have increased specifically the frequency of all 
V.4  CDR2  regions,  were reamplified with the S primers. 
After reamplification,  only the rearranged DNA yielded  an 
appropriate product (lane 8). Products corresponding  in size 
to  the specific mutated sequence  never were detected  with 
germline DNA  (lane  7).  Faint bands corresponding to the 
G products  can be seen for each sample (lanes 7 and 8) be- 
cause of the transfer of G primers from the original reactions 
of lanes 3 and 5. Most importantly,  DNA sequence analyses 
of the isolated  G and S bands from  lanes  7 and 8,  respec- 
tively, revealed identity with those presented in Fig.  1 (data 
not shown). 
As a further  specificity  control,  these primers were used 
to amplify the G and S sequences from another patient whose 
CLL B cells used the same Ig V. gene (4.21;  patient  001). 
An appropriately sized product was obtained from rearranged 
DNA with the G primers (lane 11), but not with the S primers 
(lane  12).  In addition, products  could not be found when 
the G product  was reamplified with the S primers (lane 13), 
indicating that the S sequence was uniquely expressed only 
in CLL 055 B cells and not in a patient using the same ances- 
tral V,4 gene.  Identical results were obtained by performing 
similar  studies  with patient  030  (data not  shown). 
Southern Blotting Analyses.  A  second approach involved 
the probing of unrearranged DNA with radiolabeled oligo- 
nucleotides  specific for the mutation-specific  or conserved se- 
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ranged DNA were amplified with the same sets of general 
G primers described above and then exposed to probes com- 
plementary to either the unique CDK2 sequence or the con- 
served FR sequence as a positive control. Fig. 4 indicates the 
results of these experiments for patient 030.  Hybridization 
with the mutation-specific probes occurred only with the rear- 
ranged DNA, whereas hybridization of the conserved probe 
was seen with both the unrearranged and rearranged DNA. 
These differences in binding of the mutation-specific probes 
occurred despite the use of longer incubation times (16 vs. 
2 h) and less stringent hybridization buffers and washing reg- 
imens (2 vs. 0.1  x  SSC; room temperature vs. 40~  than 
those used for the conserved probes. 
D  andJ,  Gene Segment Analyses 
The sequences of the D and JH segments expressed by the 
CD5 + CLL B cells are listed in Fig.  5, A  and/3. 
Nonrandom J,  Gene Usage.  JH5  and J,6  gene segments 
were used by six of the seven patients. Surprisingly, there 
were  no  examples  of J.4  gene  use  in  this  cohort,  even 
though  this  is  the  most  commonly used J,  segment  in 
healthy adults (19). D  gene use appeared random, although 
homologous germline D  segments could not be accurately 
defined in two patients (030  and 055). 
Somatic Diversification  of D andJ, Segments.  Among those 
CLL B cells with clearly definable D segments, varying degrees 
of identity with the germline gene segments existed (Fig. 
5 A), with patients 001 and 057 being the most homologous 
(92.8 and 90.5%) and patients 033, 039, and 040 being the 
least (67.7,  58.8,  and 47.7%, respectively).  Ancestral germ- 
line D  segments could not be assigned for patients 030 and 
055. Indeed, in these cases, it appeared that the majority (030) 
or the entire (055)  D  segment was deleted at the time of 
recombination and replaced by N addition. It is noteworthy 
Figure  4.  Absence  of  CLL 
030-specific sequences in germ- 
line  DNA as assessed  by Southern 
blotting. Genomic DNA  from 
either B cells or neutrophils  was 
amplified  by PCR by use of the 
general primer pairs for patient 
030 (G: 30.G.Fwd. CCGCCA- 
AGCTCCAGAGAAGG  and 30. 
G.Rev.  5'GGCATTGTCTCT- 
GGAGATGG) and  transferred 
onto nylon membranes. Blots 
were hybridized  first with a mutation-specific  32p-labeled probe (5'CAG- 
TATTAGAACTGATGGGG),  and after stripping by incubation  at 72~ 
for 1 h in 2.5 mM Tris-HC1 (pH 8.0), 0.1 mM EDTA, and 0.5 mM so- 
dium pyrophosphate,  were  hybridized  with the conserved  sequence  probe 
(5'GTGAAGGGCCGATTCA).  For the mutation-specific  probe, hybrid- 
ization was carried out at 42~  overnight; for the conserved sequence 
probe, hybridization  was performed  at the same temperature  for 2 h. For 
the conserved  sequence  probe, blots were washed  twice  at room  tempera- 
ture for 15 min with 2 x  SSC, 0.1% SDS, and then once at 40~  for 
30 min with 0.1  x  SSC, 0.1% SDS. For the mutation-specific  probe, 
washes were performed  under less stringent conditions  with 2 x  SSC, 
0.1% SDS, at room temperature for 15 min. 
that the V. genes of these patients were two of the most 
divergent from their germline counterparts (Fig.  1). 
The J, segments also show significant alterations from the 
germline, with examples of both trimming at the D-J joints 
and internal deletion (Fig.  5 B).  Furthermore,  significant 
numbers of N additions were identifiable for all patients ex- 
cept 040. 
Finally, presumptive nucleotide substitutions were found 
in the J,  and D  segments of all patients in whom likely 
germline progenitor D segments could be identified. Patients 
039 and 040 are noteworthy since in both cases the level of 
VH gene diversification  was negligible, whereas the levels of 
DJ. mutation were considerable. 
Deduced Amino Acid Differences in CDR3.  The nucleo- 
tide changes in the D  and J, segments resulted in CDR3 
lengths that were quite disparate, ranging from 11 to 23 amino 
acids (Fig. 2 A). A dramatic similarity in amino acid sequence 
was found in the CDR3 of patients 039 and 057.  This se- 
quence similarity includes an identical stretch of 6 amino acids 
that is separated by four mismatches from another identical 
stretch of 5 amino acids. 
Reidentification of CLL-unique  Sequences in Freshly 
Isolated CD5 § CLL B  Cells 
Since this study spanned 3 yr, attempts were made to de- 
termine if  new mutations had occurred in vivo over this time 
frame. Patients 001, 030, 033, 039, and 057 were reanalyzed. 
Patients 055 and 040 could not be included in this evaluation 
since the former was treated with fludarabine that essentially 
eliminated circulating CLL B ceils, and the latter had died. 
The unique V  gene arrays that had been created by muta- 
tion, N  addition, and D/J segment substitution and dele- 
tion served  as unequivocal signatures of the CLL clones. 
RNA was obtained from freshly isolated B cells, reverse 
transcribed, amplified with appropriate patient-specific  FR2 
upstream primer and the C'y downstream primer,  and se- 
quenced.  In three patients (001, 033,  and 039),  the newly 
defined sequences were identical to those listed in Fig. 1 (data 
not shown). A single-point alteration that was not produc- 
tive of an amino acid change was found in patient 030.  The 
most significant differences  were found in patient 057,  in 
whom three point mutations in CDR 2 and 3 were detected 
among two clones; one of these (G ~  A) resulted in an amino 
acid change (Ser ~  Asn)  at codon 52  of CDR2. 
VL Gene Segment Analyses 
Fig. 6 lists the Ig VL gene sequences determined and the 
computer comparisons with the presumed germline coun- 
terparts. 
Nonrandom V~ Gene Family Use.  Of the six CLL clones 
expressing  r  chains,  five used a V~I  family gene (patients 
030,  040,  055,  and 057).  However, unlike the Ig V.4 gene 
use,  which  was  restricted  to  only two  individual family 
members, four different V~I family genes were represented 
(Fig.  6 and Table 1). 
Different Degrees of Similarity with Germline V~ Genes That 
Parallel Those of the Corresponding VH Gene.  The V~I genes 








A  D GENE  SEGMENTS  AND  N REGION  ADDITIONS 
N  ~  N 
DIU~ 
AGGATATTGTAGTGGTO~TA~'I~2  TACTCC 
GCG  TCTCGCTTT  .............  AA.CT.  .  .  C ....  A  TCACAGTTTT 
GCGAGA  G..  A,  GG.AAT  ....  G ....  GCAAA...  A. 
DaX]9 
GTA  TTACTATGATAGTAGTGGTTATTA  C 
GCGAGG  TG  ........ T .....  C .............  CCCCG 
mix 
GGTATAACTGGAACTAC 
GCGAGC  TCCAGAG  ...... G.  A.  C.  GC.  GG  TGGTCATCT 
GGGTATAGCAGCAGCTGGTAC 
GCGAGA  CATCTG  .  .  A .................  T  GGGGCAGCC 
GCAAGA  GCTCACTCGCCTCACGGCAGCCACTATCC 
GCGAGA  GCCCCTCTGGGGCa~TGGGGCGG~GCTTT 
B 
Patient  CDR  3 
JH2  TACTGGTACTTCGATCTC 
CLL039  A ..........  C.C. 
JH5  ACAACTGGTTCGACTCC 
CLL057  ............  C.. 
CLL055  ..............  C.. 
CLL030  ...T 
JH6  TACTACTACTACTACGGTATGGACGTC 
CLL001  .A...T ....  TAC ......... 
CLL033  ........ C .....  T ...... C. 
CLL040  ......... 
JH GENE SEGMENTS 
TGGGGCCGTGGCACCCTGGTCACTGTCTCCTCA 
....... AG..A  ...........  C ......... 
TGGGGCCAAGGAACCCTGGTCACCGTCTCCTCA 
........ G ........................ 
....... TG .................  T ...... 
........ G ........................ 
TGGGGGCAAGGGACCACGGTCAC  CGTCTCCTCA 
.....  CA.G ...... C ................. 
.....  C..G ........................ 
.....  CA .......................... 
Figure  5.  Nucleotide sequences of the CDR.3 and 
FR.4 regions of the H  chains.  (A) Sequences  of the 
CLL D gene segments compared with their most likely 
germline counterpart.  Those listed as "unassignable" 
were not sufficiently similar to 24 reported sequences 
to make a comparative ancestral assignment.  (B) Com- 
parison  of germline and CLL JH gene segments. 
used by patients 040, 039, and 057 displayed complete iden- 
tity with the germline genes L9 and 02, respectively, and 
therefore are not listed on Fig. 6. In contrast, the VL genes 
used by patients 001, 030, 033, and 055 exhibited >15% diver- 
gence  from  the most homologous germline  counterparts. 
These levels of difference parallel those  seen among  the Ig 
VH genes of each patient. 
Differences in  Distribution of Nucleotide and Amino  Acid 
Changes Also Parallel Those of the Corresponding V, Gene. 
For patients 001 and 033, nudeotide changes were distributed 
throughout  the VL segment,  whereas for patients 030 and 
055 these clustered either within CDR 1, 2,  and 3 for pa- 
tient 030 or in CDR 1, 2, and 3 and FR 2 for patient 055. 
The deduced amino acid VL sequence of patient 030 exhibits 
r  Framework 1  I  I"  CDR 1 
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  2"/  2"IA  27B  27(:  28  29  30  31  3IA  32 
DPL8  CAG TCT GTG CTG ACG tAG CCG C~-C TCA  GTG TCT G@O G(~: CCA GGG CAG A8@ @TC ACC ATC TCC TGC AL'T G<R] AGC AGC TCC AAC A~  ~  ~  ~  TAT  GAT 
C~LO01  ......................................  G  ........  o  ...........................  A  .......  G  ................. 
L12a  OAC  ATC  c~a  ATG /gZC  r  TCT  CCT  T~  J~'C  CT~  TCT  OC~  r  OTA  OG~  ~LC  ~  ~  ~  A~  ~  ~  ~  ~  ~  ~  ~z~r  ATT A~T  ~  TOO 
C'LL030  ....................... c  ............................................................  o...c  ....  c.. 
A27  CIAA ATT GTQ TTG ACG ~J&/~  TCT CCA GGC ACC CTG TCT TTG TCT CCA G~G GA/% AGA ~  ACe C~  ~  ~  ~  ~  ~  ~  AGT GTT AGC AGC ~  TAC 
CLL033  ....................................................  A.  ,T  .................................  T  ,  .T  .C  .... 
LI9  GAC ATe CAG ATG ACC CA~ TCT CC.A TCT TCT GTG TCT GCA TCT GTA GG~ GAC AGA GTC ACC ATC ACT TGT CGG ~  AGT CAG  GGT ATT AGC AGC  TGG 
CLLOS5  ......................................  T  .........................  0  ...............  A  CA  ........  C  .... 
I  ]  Framework2  I  I  CDR2  561  5  f 
33  34  35  36  3"/  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  ?  58  59  60  61  62  63  64  65  66  6"/  68 
DPL8  GTA CAC TGG TAC CAG CAO CTT CCA GGA AC.A GO~ CO~ AAA C'fC CTC ATe T&T GGT /~T A~R: ~  ~  ~  ~  ~  ~C  ~  ~  ~  ~  T~  ~  T~  ~  T~  ~ 
CLLOOI  ,.o  ......................... k  .............  Q .....  c  ................................  o  ......................... 
LI2a  TTG GCC T~  TAT CAG O.A~ AAA OCA ~  AAA GCC CC'T AAG CTC CTG ATC TAT A/~S OCG TOT AGT ~A  ~  ~  ~  ~  ~  T~  ~  ~  ~  ~  ~  ~  T~  ~ 
CLL030  A .....................................  A  .............  O.  .OA  .  .C  ......  c  ..............  CT  ......................... 
A27  TTA GCC TGG TAC ~  CA~ AAA CCT GGC CAG ~CT COC AGO CTC CTC ATC TAT ~T  GCA TO(: A~= A~@ ~  ~  ~  A~  ~  ~  ~  ~  ~  ~  ~  ~  T~  ~ 
eLL033  .........................................  G  ....  T  ......  A  ................  C  .................................... 
LI9  TTA GCC TGG TAT CAG ~A~ AAA CCA ~  AAA GCC CCT A~  CTC CTG ATC TAT (~'T GC.A T(R= AGT TT~ C.~% ~  ~  ~C  ~  T~  ~  ~  ~  ~  ~  ~  T~  ~ 
CLL055  ...................  G  ......................  T  ....  C.  .G  ................  G ...................................... 
F .... rk3  I  8  e[ -- CDR 3 
69  70  71  72  73  74  7S  76  7~  78  79  $0  el  ~2  e3  84  85  86  87  ￿9  9  9O  91  92  93  94  95  9SA 9 
DPL8  AC~ TCA ~CC TOC CTG  GCC AT(= ACT GG~ CTC CA@ OCT GAG r  ~  GCT ~AT TAT TAC T~= CAG T~  TAT ~AC A~C ~  CTG AGT GGT 
(:LLO01  G .........................  A  ......  T ............................. A .............  G  ....  A.  AT~ 
Ll2a  ACA GAA TTC ACT CTC ~  ATC A~C AGC CTG CA~ OCT GAT (M&T TTT GCA ACT TAT TAC TGC CA~ CA~ TAT AAT AGT TAT TCT 
CIJ.O30  .........................................  c  ..........................  c  CT..A...C  C.~ 
A27  ACA GAC TTC ACT CTC AC~ ATC AGC A~A CTG  GAG CCT  G~A  ~AT TTT GCA GTG TAT T/U= T~T CAG ~  TAT OGT ~  TC.K OCT 
CLL033  ..............................................................  A  ...........  T  .T .... 
LI9  ACA GAT TTC ACT CTC Af2T ATC A~C Afi~ CTG CAG CCT G~A GAT T'FT GC.% ACT TAC TAT T@T C4&A ~  ~  ~  ~  ~  ~ 
CrL055  ...  C  ..................  C.  u  ..............................  T ......... A  .............. G 
Figure  6.  Nucleotide sequences  of VL genes.  Since the VL gene sequence  for patient 040 is identical  to the L9 germline gene and those of patients 
039 and 057 are identical  to the 02 germline gene, they are not listed.  These sequence  data are available from EMBL/GenBank/DDBJ under accession 
numbers  X84340-X84346. 
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H  chain 
Most 
homologous  Likely 
V.  germline  V.  gene  germline 
Patient  C.  CRI*  family  V.  gene  difference  D  segment  J. 
Types of diversification 
SomaticH  Possible 
N  addition/  mutation  antigenic 
trimming s  V,/DJ,  selection 
% 
CLL 001  3/1  -  4  4.21  5  D21/9 
CLL 033  3/1  F4  4  4.21  8  DLR2 
CLL 055  3/1  F4  4  4.21  9  ? 
CLL 039  3/3  -  4  4.18  1  DM1 
CLL 057  3/3  -  4  4.18  1  DN1 
CLL 030  3/1  F4  3  Hll  6  ? 
CLL 040  3/1  -  3  1.9III  2  DLR2 
L chain 
6  +/+  ++/++  - 
6  +++/+  +++/+++  - 
5  +++/-  +++/+  +/- 
2  ++/-  -/+++  + 
5  ++/+  -/+  + 
5  +++/+++  ++/+  + 
6  -/+++  -/+++  + 
Types of diversification 
Most 
homologous  Somaticll  Possible 
VL  germline  VL gene  N  addition/  mutation  antigenic 
Patient  CL  CRI*  family  VL gene  difference  JL  trimmings  VL/J~  selection 
% 
CLL 001  X  -  M-c  DPL8  6  JX2/3  -  / +  +  + / +  - 
CLL 033  K  3I  KIIIb  A27  5  Jgl  -  / +  + + / +  - 
CLL 055  K  3I  fcI  L19  7  Jx4  + / +  + + + / +  + / - 
CLL 039  g  -  KI  02  0  JK2  + / + +  -  / +  + 
CLL 057  K  -  ~I  02  0  JK1  + / +  -  / +  + 
CLL 030  K  31  KI  L12a  7  JK4  -  / +  + +  + / +  + 
CLL 040  K  3I  gI  L9  0  JK1  -  / +  -  / +  - 
* Adapted, in part, from references 9 and 22. 
* Cross-reactive idiotypic (CRI) determinants detected by solid-phase RIA as described (33, 34). 
S Notations preceding the slash (/) relate to the relative numbers of N additions; notations after the slash relate to degrees of trimming at joints. 
II Notations preceding the slash relate to the relative number of mutations in V. or Vt; those after the slash relate to DJ. and Jt  segments. 
R/S substitution ratios >3 for the CDR and <1 for the FR 
(Fig. 2 B). These patterns closely resemble those seen for the 
corresponding H  chain  gene in almost every case. 
Random Use of  JL Gene Segments.  Unlike the nonrandom 
use  of J.,  JL  families  are  used  in  an  apparently  stochastic 
fashion (Fig. 7). In every case, there is evidence for trimming 
of the JL segments as well as examples of a limited number 
of N  additions in patients  039, 040,  and 057 (Fig.  7).  The 
combination  of trimming  and  N  addition  has  resulted  in 
VL-J~ junctional  diversity in each case. 
Discussion 
The preceding data demonstrate that certain CD5 + CLL 
B cells display skewed use,  somatic diversification,  and evi- 
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dence consistent with antigenic selection of their Ig H  and 
L chain V region genes. Table 1 collates the genetic data from 
this  study and the serologic data from a companion study 
(9) to provide a comprehensive view of the characteristics of 
these cells. 
Gene Segment Use.  Evidence for nonrandom use of both 
H  and L  chain V  region genes was manifested  as  an over- 
representation  of  V.4  and  J~I  family  genes  and  under- 
representation  of the JH4 gene segment.  VH4 gene use was 
restricted further to only two (4.21  and 4.18)  of the 12-16 
members  of the  family (18).  A  restriction  to  specific gene 
members  was not  seen for J~I,  although  the 02  gene was 
expressed  in  two patients. 
The  frequency of V.4  gene  use  among our  patients  is CDR3 
Patient  I .....  VL ....  I 
CLL  001  ......  AAT  ATT 
Framework  4 
.......................  JL ......................  I 
TG  TG  GTA 
..C  ..G 
G  TGG  ACG 
CLL  033  ......  TTA  CCT  .C  .... 
CLL  040  ......  TAC  CCT  CA  ... 
CLL  057  ......  ACC  CCT  C  .A  ... 
CLL  039  ......  ACC  CCT  CGG 
TG  TAC  ACT 
.G. 
G  CTC  ACT 
CLL  030  ......  TAC  CCG  G ..... 
CLL  055  ......  TTC  CCG  A ....  C 
TTC  GGC  GGA  GGG  ACC  AAG  CTG  ACC  GTC  CTA  G 
........  G  .......  G ..........  G..  . 
TTC  GGC  CAA  GGG  ACC  AAG  GTG  GAA  ATC  AAA  C 
.......  G ....................... 
Figure  7. 
TTT  GGC  CAG  GGG  ACC  AAG  CTG  GAG  ATC  AAA  C 
TTC  GGC  GGA  GGG  ACC  AAG  GTG  GAG  ATC  AAA  C 





significantly different from the potential repertoire available 
in the germline (exact goodness of fit test;/) <0.005;  20) but 
not from a composite of the available CLL V gene sequences 
(21). Nevertheless,  the overexpression of the specific V.4 
genes 4.21 and 4.18 is striking considering  that two prior 
studies failed to document such a restricted use of individual 
genes within a V. family in CLL B cells (23, 24). Further- 
more, the absence of J,4 use by our patients'  B cells is sig- 
nificantly different not only from healthy adult blood B cells 
(p <0.003;  19) but also from most CLL patients ~  <0.002; 
21). In addition,  the overrepresentation of V~I family genes 
in  our  patients  differs  from  that  of  the  V~IIIb gene 
humkv325/A27 reported in other cohorts with CLL (25), 
although one of our patient's  (033) CLL cells did use this 
gene. Finally, the biased use of Ig genes by our CLL patients 
extends to C, and involves the restricted use of IgG1 and 
IgG3 and the absence of IgG2 (9, and Table 1). The lack of 
IgG2 expression is striking since in healthy adults, B cells 
producing this subclass are of equal frequency to those pro- 
ducing IgG1  (26). 
Thus our data support the principle that CD5 + CLL B 
cells demonstrate biased use of Ig H  and L chain gene seg- 
ments. Those biases observed in our patients that differ from 
those reported previously may indicate different selective  pres- 
sures in these IgG-producing CLL ceils compared with most 
CLL patients that develop a clonal expansion of IgM-bearing 
B cells (92-95%; 27). These findings favor the concept that 
the V gene biases in CD5 + B cells can result from antigen 
selection (28, 29) rather than inherent processes  programmed 
before antigen receptor  expression (30). 
Somatic Diversification.  Some level  of somatic diversification 
was found in every case. These diversification events occurred 
both at the time of gene segment recombination  as well as 
after the attainment of a competent B cell antigen-receptor 
complex.  For example, at  the times  of D-J.  and V.-DJ. 
joining and VL-J~  joining, varying levels of N addition and 
trimming occurred in the H and L chains of most patients. 
It is noteworthy that the combined effects of trimming and 
N addition in VL, however, conserved CDR3 lengths of nine 
amino acids. It is now known that ~20% of normal human 
B cells exhibit additions of nucleotides at the VL-JL  junction 
that can alter CDR3 length (31), although longer CDR3 
lengths appear to be more frequent in patients with inflam- 
matory diseases like rheumatoid arthritis  (32). 
Multiple  somatic changes not related to the recombina- 
tion process also occurred in regions of these genes. Four pa- 
tients showed significant variations of their H and L chain 
V genes from the reported germline counterparts.  The level 
and location of these differences in the H and L chains were 
quite similar within an individual patient's leukemic clone. 
The possibility that these differences reflected the presence 
of heretofore unreported gene segments was ruled out for 
the two patients  studied in detail (030 and 055). Interest- 
ingly, a cross-reactive idiotype found almost exclusively on 
mutated IgG autoantibodies and not within the germline (F4; 
33) was expressed by these two IgG molecules as well as that 
produced by patient 033 (9 and Table 1), providing serologic 
corroboration of the molecular data obtained. 
However, mutations were not seen in the V. genes of all 
patients studied. Specifically the two patients using the V. 
4.18 gene demonstrated very minor differences  from the germ- 
line counterpart. In contrast, the three patients that used the 
V, 4.21 gene demonstrated significant somatic diversifica- 
tion. This observation confirms those recently reported (21, 
35) on the discordant occurrence of mutations in these two 
gene segments in CLL. 
The diversification detected in the IgG-producing B cells 
of these patients is not restricted to the V. or VL segments. 
Essentially all of the patients demonstrated differences from 
the germline D and J, segments, and every patient showed 
diversity at  the VL-J~ junctions.  These latter  changes  are 
striking since they result in the acquisition of a positively 
charged arginine residue at the joints in two patients  (039 
and 057) and the creation of a threonine residue one position 
downstream from the joints in five  patients (030, 033, 040, 
055,  and 057). 
Most previous reports  suggest  that CD5 + CLL B cells 
undergo little somatic diversification (2), although certain 
studies have contained occasional patients whose V genes di- 
verge from the presumed germline counterparts (for review 
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tation in CLL is that of Cai et al. (6), who documented ex- 
tensive and selected mutations in IgM-producing CLL B cells 
that used the V.251 gene. This group of patients was some- 
what atypical, however, since •30%  of the patients studied 
used this gene segment,  a frequency not in line with most 
other studies. Since neither the frequency of V~251 use nor 
the presence of extensive mutations  could be corroborated 
by Rassenti and Kipps (7), these investigators suggested that 
the patients studied by Cai et al. (6) might not be representa- 
tive of the disease  or that  subsets of patients'  CLL B cells 
might  differ in their ability to develop somatic mutations. 
In support of the latter possibility are reports of V. (36) and 
VL (37) gene mutations in CLL patients whose B cells lacked 
CD5 expression. Although our patients display typical fea- 
tures of CLL and their expanded leukemic clones express CD5, 
they do comprise a subset defined by the production of IgG 
antibodies (9). Thus, our data are compatible with both the 
studies of Cai et al. and Rassenti and Kipps, providing clear 
evidence for somatic diversification of V  region genes in a 
subset of leukemic CD5 + B  cells  that  have undergone  an 
isotype class switch. Furthermore,  our studies indicate that 
mutations  can occur in the V  genes of both the H  and L 
chains and that the numbers and locations of these changes 
are closely paralleled in individual patients. However, it should 
be noted that  the extent of mutation documented in these 
leukemic CD5 + B cells is not as extensive as that  observed 
in CD5 + B cells  from  sites  of chronic inflammation  (38). 
Antigen Selection.  The diversification detected in this study 
is distributed differently among the V  region  genes of the 
various patients.  In some cases (e.g., patients 001 and 033), 
nucleotide differences are randomly distributed,  whereas in 
others  (e.g.,  patient  030)  these are  clustered in the CDR. 
In contrast,  patients 039, 040, and 057 demonstrate virtu- 
ally no changes in their VH or V~ segments, but exhibit ex- 
tensive changes in D  and JH and unique changes at the VL-JL 
junctions. Although the H chain disparities could have arisen 
by V. gene replacement,  the lack of mutation  seen in the 
corresponding VL segments of these same patients suggests 
that  this mechanism  is a less likely explanation. 
These somatic changes result in significant and differing 
numbers of replacement changes at the amino acid level.  It 
is accepted that the presence of an R/S ratio t>3 in the CDR 
with  lower ratios in the FR suggests antigen  selection of 
the somatically generated substitution (39). These criteria are 
met for the V. of patient 030 (K/S >7 in CDR and 0.6 in 
FR). In addition, the clustering of replacement substitutions 
in CDR2  and between amino  acids  73 and  76 of FR3 of 
patient 055 suggest antigen selection, since this portion of 
FR3 of the V. is known to affect antibody binding to DNA 
(40, 41)  and  the conformation  of the antigen-binding  site 
(42).  Similarly,  the VL of patient  030 has  an R/S substitu- 
tion ratio clearly compatible with antigen selection (CDR, 
3.3;  FR, 0.3),  and the V~ of patient  055 has  an R/S ratio 
and pattern  similar  to that  in V.,  again with involvement 
of the amino acids in the CDR and FR3, at or around posi- 
tion  76 of the L chain. 
However,  the most  striking  indications  of selection are 
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the amino add changes that have occurred in the CDR3 of the 
H  and  L  chains  of patients  039 and 057.  Indeed,  despite 
the use of different germline D  and J. genes,  the addition 
of different numbers and types of nucleotides at the joints, 
and the difference in levels of trimming or deletion, identity 
at 11 of 17 amino acid positions has been achieved by somatic 
processes (Fig. 2 A). In addition, a basic arginine residue has 
been created at the VL-JL  joints in each case (Fig. 2 B). This 
also is striking since these two B cells used different J~ genes 
and exhibited different levels of trimming  and N  addition 
at  these joints.  Considering  that  both patients'  CLL cells 
use the same,  virtually nonmutated  V. (4.18) and VL (02) 
genes, the amino acid structure of their two antigen receptors 
is >95% similar.  Thus, there appear to be selective pressures, 
presumably antigenic,  to mutate the CDR3 of V, and the 
V-J junctions of V~ to yield remarkably similar amino acid 
sequences and maintain the identity of the rest of the com- 
bining sites in these two patients. Finally, since both patients' 
CLL cells use qr3 H chains, one must consider strongly that 
a similar type of antigenic drive and cellular help has been 
involved in their diversification and  selection processes. 
Implications for CLL and Its Evolution.  These data dem- 
onstrate conclusively that somatic mutations of Ig V region 
genes can be found in certain CLL clones. However, the data 
do not indicate when these mutations occurred in relation 
to the leukemogenic event(s). If they occurred before, then 
our data would be consistent with the notion that transfor- 
mation renders these cells/genes less "mutable." In addition, 
they would indicate that the transformation  event need not 
occur in a relatively immature B cell whose V genes still have 
a germline-like sequence,  as has been suggested recently (21). 
In contrast, if these mutations are ongoing, this would sug- 
gest that these cells behave more like their normal counter- 
parts. Our 3-yr follow-up study of the accumulation of only 
limited numbers of mutations between FK2 --~ JR in five pa- 
tients is relevant here. However, this issue needs more exten- 
sive study in more patients. 
Our data also are consistent with the idea that antigenic 
stimulation  may be involved in the clonal amplification  in 
this disease. Studies of other lymphoid malignancies are com- 
patible  with  this  view  (43-45).  Considering  the  known 
propensity of CD5 + CLL cells to be autoreactive (3-5), au- 
toantigenic drive through  the B cell antigen receptor is an 
attractive possibility.  However, surprisingly,  the IgG anti- 
bodies  secreted  by  these  CD5 +  CLL  cells  did  not  react 
significantly with  a panel of six classical  autoantigens  (9). 
This observation appears to relate at least in part to antibody 
valency (9).  However, in  addition,  the  somatic mutations 
documented here may have sufficiently altered their binding 
sites away from reactivity with an original (auto)antigen in 
favor of another  or of an exoantigen  (46,  47). 
Finally,  these studies suggest  that  our understanding  of 
the triggering capabilities  and requirements for CLL cells may 
be too simplistic.  Somatic diversification of normal  CD5- 
B cells appears to be initiated by antigen, require T cell help, 
and  occur in  germinal  centers,  whereas CD5 + B cells  are 
considered to be triggered by T  cell-independent  antigens, 
presumably in the mantle zones of lymph nodes (for review see reference 48). However, although studies in humans sup- 
port this general view (49), others also indicate that human 
CD5 § B cells, both normal and leukemic, can respond to 
T  cell-derived stimuli (50, 51). Indeed, the preferential use 
by our patients' CD5 + B cells of 3'1 and 3'3 subclass  genes 
and the absence of 3`2 (Table 1; 9) might favor the latter mech- 
anism, since studies suggest that, in general, T  cell-depen- 
dent protein antigens induce switching to IgG1 and IgG3, 
while switching to IgG2 frequently can be a function of T 
cell-independent polysaccharide  antigens (for a review see ref- 
erence 52).  Finally,  since at least in the murine system it is 
thought that CD5 + B cells may represent a different cellular 
lineage (53)  that follows a distinct differentiation pathway, 
such cells might use different mechanisms or anatomic sites 
to achieve somatic diversification. Similarly, diversification 
might occur in a distinct subset of these cells, due either to 
inherent subset differences or differences in accessory cell or 
T  cell helper function. The latter might be especially  rele- 
vant since we have shown previously that most IgM-producing 
CLL patients have diminished T  cell helper function (54). 
The surface  phenotypes of these IgG+CD5 + CLL B cells 
and their T  cell functions are being evaluated to determine 
whether unique features exist for these particular cases. 
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